US · Healthcare · Biotechnology
EPS came in at -1.52 against a street estimate of -1.16 — a miss of 31.0%.
Analysts rate Palvella Therapeutics, Inc a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $230.53.
CONFIDENT PVLA achieved Phase III success in microcystic lymphatic malformations, secured FDA rolling review, and submitted first NDA module. On track for full NDA submission H2 2026 and potential approval H1 2027. $251M cash supports robust commercial launch. Q2 2026 No geographic segments discussed; U.S.-focused strategy only. Analysts probed patient population sizing (confirmed >30K conservatively), DSAP vs. angio timing (both on track), and cVM placebo design (FDA alignment pending). Management emphasized data-driven epi, schedule discipline, and collaborative FDA approach. No surprises. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| Suvretta Capital Management, LLC | 8.01% |
| Bvf Inc | 6.67% |
| Jennison Associates LLC | 6.67% |
| Frazier Life Sciences Management, L.P. | 6.12% |
| First Light Asset Management, LLC | 5.36% |
| BlackRock Inc | 4.77% |
| Frontier Capital Management CO Inc | 3.32% |
| Vanguard Capital Management, LLC | 3.31% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 PALVELLA THERAPEUTICS, INC. — 10-Q SUMMARY (Q2 2026) --- HEADLINE NUMBERS • Cash Position: $187.8 million in cash and equivalents + $62.8 million i | 2026-08-04 |
| Results announced · Q3 2026 PALVELLA THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash, cash equivalents, and short-term investments: $250.6 million as of | 2026-08-04 |
| Company announcement · Q3 2026 PALVELLA THERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Company: Palvella Therapeutics, Inc. (Nasdaq: PVLA) • Report Date: July 14, 2026 • Head | 2026-07-14 |
| Board / officer change · Q2 2026 PALVELLA THERAPEUTICS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Board size increased from 7 to 8 members on June 29, 2026 • New director granted o | 2026-06-30 |
| Board / officer change · Q2 2026 PALVELLA THERAPEUTICS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Outstanding common stock as of April 13, 2026 (record date): 14,323,686 shares • S | 2026-06-16 |
| Quarterly report · Q1 2026 PALVELLA THERAPEUTICS, INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash & Equivalents: $206.4 million at March 31, 2026 vs. $58.0 million at Dece | 2026-05-07 |
| Proxy statement · Q2 2026 PALVELLA THERAPEUTICS, INC. – 2026 PROXY STATEMENT SUMMARY --- CEO TOTAL COMPENSATION • Wesley H. Kaupinen (President and CEO) received $1,107,500 | 2026-04-30 |
| Annual report FY2025 PALVELLA THERAPEUTICS, INC. — 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company completed merger on December 13, 2024, changing name from | 2026-03-31 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Split | 1 : 80 effective Apr 23, 2024 | 2024-04-23 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Palvella Therapeutics, Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.